SK-N-BE(2)-C: Human Neuroblastoma Cell Line (ATCC CRL-2268)

SK1980-532

SK-N-BE(2)-C: Human Neuroblastoma Cell Line (ATCC CRL-2268)

SK1980-532
Share
Share

Description

SK-N-BE(2)-C is a clonal subline of the SK-N-BE(2) neuroblastoma cell line. Like the parental cell line, these cells display MYCN amplification. Treatment with trans-retinoic acid differentiates these cells into a distinct neuronal phenotype. These cells display high levels of tyrosine hydroxylase activity and dopamine-b-hydroxylase activity.

Source

This cell line is a subclone of the SK-N-BE(2) neuroblastoma cell line. The parental cell line was established in 1972 from a metastatic site (bone marrow) in a two-year-old Caucasian male with malignant neuroblastoma.

Inventors

  • June L. Biedler, PhD, former Chairman, Cell Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering
  • Barbara A. Spengler, formerly at Sloan Kettering Institute, Memorial Sloan Kettering

Key References

  • Ciccarone V et al. (1989) Phenotypic diversification in human neuroblastoma cells: expression of distinct neural crest lineages. Cancer Research 49: 219-225 (PubMed ID: 2535691)
  • Qiao J et al. (2012) PI3K/AKT and ERK regulate retinoic acid-induced neuroblastoma cellular differentiation. Biochemical and Biophysical Research Communications 424: 421-426 (PubMed ID: 22766505)

Licensing Information

This cell line may be licensed nonexclusively for research or commercial purposes.

  • Express License:  For internal research purposes by a for-profit entity:  1) Fill out MSK’s ATCC Express License, see here for links to the online fillable ATCC Express License, as well as a PDF version.  2) After execution by MSK, you will receive a signed copy, and can then place your order with ATCC. For detailed guidance on how to fill out this webform, see here. Please note:  In order to streamline and expedite the licensing of select MSK cell lines, the terms of this non-exclusive license are non-negotiable. This license is only available for select cell lines, including this one. Once this license has been executed by MSK, you will receive a signed copy and payment instructions; all payments up to $10,000 must be made by credit card.
  • Commercial License: Contact MSK’s Tangible Materials team at [email protected].
  • For non-licensing requests from academic-research institutions: Contact Frances Weis-Garcia, PhD, Associate Laboratory Member/Head, Antibody & Bioresource Core Facility, MSK, 646-888-2354, [email protected]

Stage of Development

Ready to use

Indications